Trinity Biotech (TRIB) Non-Current Assets (2009 - 2025)

Trinity Biotech (TRIB) has reported Non-Current Assets for 17 consecutive years, with $69.3 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Assets rose 11.42% year-over-year to $69.3 million in Q4 2025, while the trailing twelve-month figure through Jun 2025 was $66.6 million (up 37.75% YoY) and the FY2025 annual result came in at $69.3 million, up 11.42% from the prior year.
• Non-Current Assets climbed to $69.3 million in Q4 2025 per TRIB's latest filing, from $66.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for TRIB reached as high as $69.3 million in Q4 2025 and fell as low as $19.1 million in Q2 2023.
• A 5-year average of $44.9 million and a median of $47.0 million in 2021 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets plunged 61.78% — and 2024, when it surged 204.82%.
• Year by year, Non-Current Assets stood at $46.2 million in 2021, then dropped by 1.67% to $45.4 million in 2022, then sank by 55.11% to $20.4 million in 2023, then jumped by 204.82% to $62.2 million in 2024, then rose by 11.42% to $69.3 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $69.3 million, $66.6 million, and $62.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.